Amgen's Imdelltra plus Imfinzi Cuts Death Risk 58% in Extensive-Stage Small Cell Lung Cancer

4.8 · 7d ago · WORLD

The Facts

  • Full results from a late-stage trial released Saturday show adding Amgen's Imdelltra to AstraZeneca's Imfinzi reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer. CNBC only
  • Median overall survival was 21.1 months with the combination versus 12.7 months with Imfinzi alone. CNBC only
  • Amgen said nearly 80% of patients on both drugs were alive at one year, versus 53% on Imfinzi alone. CNBC only
  • The trial tested the combination as maintenance therapy in patients who had received initial Imfinzi plus chemotherapy and whose cancer had not progressed. CNBC only
  • Lead investigator Dr. Jacob Sands said benefits were seen across subgroups, including patients whose cancer had spread to the brain or liver. CNBC only
Dive deeper · 4 more factsShow less
  • The study was presented at the European Society for Medical Oncology Congress and did not test the combination against other first-line treatment approaches. CNBC only
  • Imdelltra is currently approved for small cell lung cancer that has progressed on or after platinum-based chemotherapy. CNBC only
  • Imdelltra posted $288 million in sales in Q2, up 115% year over year, and $627 million in global sales in 2025. CNBC only
  • There are roughly 31,000 new small cell lung cancer cases in the U.S. each year, and an estimated 60% to 70% are diagnosed at the extensive stage. CNBC only

Context

Amgen reported full late-stage trial results showing that adding Imdelltra to AstraZeneca's Imfinzi as maintenance therapy substantially extended survival in extensive-stage small cell lung cancer compared with Imfinzi alone.

Imdelltra works by binding DLL3 on cancer cells and CD3 on T cells, while Imfinzi blocks PD-L1. Sands said the 21-month median survival figure may change with longer follow-up. Amgen's chief medical officer Dr. Paul Burton said the data could change the standard of care.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 2.

6 Science & Tech Analyst A peer-reviewed late-stage trial showing a 58% reduction in death risk in an aggressive cancer is a significant clinical result, but it affects a relatively narrow patient population and is a single trial presented at a congress, not an immediate broad-impact event.
6 Critical Reader A verified late-stage trial showing a 58% reduction in death risk is a meaningful clinical result for a niche but serious cancer population, though it is company-reported full data for an existing approved drug rather than an immediate, broad change in practice.
5 News Editor A concrete positive late-stage trial result showing a large survival benefit for a niche cancer population is newsworthy and of moderate importance, but it is a single-company trial presentation at a medical conference affecting a relatively small patient group rather than broad, immediate public impact.
5 Business Analyst This is a significant positive late-stage trial readout with a large survival benefit in a deadly cancer, moderately important for Amgen and the oncology market but not a broad market-moving or regulatory event, and it is a clinical data release rather than a corporate or policy shift.
4 Policy Expert This is a clinical trial result presented at a medical conference, not an enacted law, ruling, or regulatory approval, though it is significant for a specific patient population and could influence future treatment standards.
4 Informed Citizen This is a significant clinical trial result with a large survival benefit for a serious cancer, but it concerns a single-company trial presented at a conference, not yet approved or changing practice, so its immediate impact on ordinary people is limited.
4 Global Affairs Analyst This is a notable positive late-stage trial result in a serious cancer with a substantial survival benefit, but it is a single company's clinical data presented at a conference rather than a broad-impact event, so it sits in the minor-to-moderate range.

Source

← All stories